Literature DB >> 9151840

cis-Acting inhibitory elements within the pol-env region of human T-cell leukemia virus type 1 possibly involved in viral persistence.

A Saiga1, S Orita, N Minoura-Tada, M Maeda, Y Aono, M Asakawa, K Nakahara, R Kubota, M Osame, H Igarashi.   

Abstract

Human T-cell leukemia virus type 1 (HTLV-1) remains latent throughout the life of the carrier, with cells containing the provirus and viral gene expression efficiently down-regulated. On a molecular level, exactly how viruses are down-regulated in vivo remains unresolved. We described here the possibility that down-regulation results from the presence of inhibitory elements within the gag-env region of the provirus in fresh peripheral blood mononuclear cells from carriers. In vitro experiments then revealed that potent cis-acting inhibitory elements (CIEs) are indeed contained in two discrete fragments from the pol region and weaker ones in the env region. The effect of CIEs is relieved by the HTLV-1 posttranscriptional regulator Rex through binding to the Rex-responsive element (RxRE), suggesting that Rex might interfere with pre-mRNA degradation and/or activate the export of mRNA molecules harboring both of the inhibitory elements and RxRE on the same RNA molecule. Thus, we propose the hypothesis that such functions of CIEs may be involved in HTLV-1 persistence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151840      PMCID: PMC191668     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  Myb protein binds to human immunodeficiency virus 1 long terminal repeat (LTR) sequences and transactivates LTR-mediated transcription.

Authors:  P Dasgupta; P Saikumar; C D Reddy; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein.

Authors:  S Schwartz; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 3.  Messenger RNA transport and HIV rev regulation.

Authors:  D D Chang; P A Sharp
Journal:  Science       Date:  1990-08-10       Impact factor: 47.728

4.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors:  S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

5.  Secondary structure of the human T-cell leukemia virus type 1 rex-responsive element is essential for rex regulation of RNA processing and transport of unspliced RNAs.

Authors:  H Toyoshima; M Itoh; J Inoue; M Seiki; F Takaku; M Yoshida
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Identification and characterization of intragenic sequences which repress human immunodeficiency virus structural gene expression.

Authors:  A W Cochrane; K S Jones; S Beidas; P J Dillon; A M Skalka; C A Rosen
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

7.  Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells.

Authors:  J G Sodroski; C A Rosen; W A Haseltine
Journal:  Science       Date:  1984-07-27       Impact factor: 47.728

8.  A 36-kilodalton cellular transcription factor mediates an indirect interaction of human T-cell leukemia/lymphoma virus type I TAX1 with a responsive element in the viral long terminal repeat.

Authors:  S J Marriott; P F Lindholm; K M Brown; S D Gitlin; J F Duvall; M F Radonovich; J N Brady
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

9.  Human T-cell leukemia-lymphoma virus type I (HTLV-I) expression in fresh peripheral blood mononuclear cells from patients with tropical spastic paraparesis/HTLV-I-associated myelopathy.

Authors:  A Gessain; A Louie; O Gout; R C Gallo; G Franchini
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1.

Authors:  R Bosselut; J F Duvall; A Gégonne; M Bailly; A Hémar; J Brady; J Ghysdael
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

View more
  7 in total

1.  mRNA instability elements in the human papillomavirus type 16 L2 coding region.

Authors:  M Sokolowski; W Tan; M Jellne; S Schwartz
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

2.  Identification of RNA instability elements in Borna disease virus.

Authors:  Ulrike Siemetzki; Mundrigi S Ashok; Thomas Briese; W Ian Lipkin
Journal:  Virus Res       Date:  2009-04-05       Impact factor: 3.303

3.  Expression of Alternatively Spliced Human T-Cell Leukemia Virus Type 1 mRNAs Is Influenced by Mitosis and by a Novel cis-Acting Regulatory Sequence.

Authors:  Ilaria Cavallari; Francesca Rende; Marion K Bona; Joanna Sztuba-Solinska; Micol Silic-Benussi; Martina Tognon; Stuart F J LeGrice; Genoveffa Franchini; Donna M D'Agostino; Vincenzo Ciminale
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

4.  Role of Nucleocytoplasmic RNA Transport during the Life Cycle of Retroviruses.

Authors:  Hisatoshi Shida
Journal:  Front Microbiol       Date:  2012-05-18       Impact factor: 5.640

Review 5.  Converging strategies in expression of human complex retroviruses.

Authors:  Ilaria Cavallari; Francesca Rende; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Viruses       Date:  2011-08-11       Impact factor: 5.048

Review 6.  HTLV-1 and HTLV-2: highly similar viruses with distinct oncogenic properties.

Authors:  Vincenzo Ciminale; Francesca Rende; Umberto Bertazzoni; Maria G Romanelli
Journal:  Front Microbiol       Date:  2014-07-29       Impact factor: 5.640

7.  Comparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2.

Authors:  Francesca Rende; Ilaria Cavallari; Maria Grazia Romanelli; Erica Diani; Umberto Bertazzoni; Vincenzo Ciminale
Journal:  Leuk Res Treatment       Date:  2011-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.